Foster Victor Wealth Advisors LLC purchased a new stake in Anavex Life Sciences Corp (NASDAQ:AVXL) during the third quarter, HoldingsChannel reports. The firm purchased 25,028 shares of the biotechnology company’s stock, valued at approximately $76,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in Anavex Life Sciences in the 2nd quarter valued at $38,000. D. E. Shaw & Co. Inc. bought a new stake in Anavex Life Sciences in the 2nd quarter valued at $120,000. Northern Trust Corp raised its stake in Anavex Life Sciences by 32.4% in the 2nd quarter. Northern Trust Corp now owns 147,445 shares of the biotechnology company’s stock valued at $497,000 after acquiring an additional 36,073 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Anavex Life Sciences by 562.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 105,179 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 89,305 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Anavex Life Sciences by 359.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 133,389 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 104,372 shares in the last quarter. Institutional investors and hedge funds own 22.34% of the company’s stock.
A number of brokerages have commented on AVXL. Janney Montgomery Scott began coverage on Anavex Life Sciences in a report on Tuesday, June 18th. They issued a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Tuesday. Dawson James began coverage on Anavex Life Sciences in a report on Wednesday, July 24th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, ValuEngine lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $9.46.
NASDAQ AVXL traded up $0.01 on Friday, reaching $2.76. The stock had a trading volume of 11,389 shares, compared to its average volume of 477,227. The firm has a fifty day moving average of $2.97 and a two-hundred day moving average of $3.00. Anavex Life Sciences Corp has a 1-year low of $1.25 and a 1-year high of $4.09. The company has a market cap of $146.63 million, a P/E ratio of -7.10 and a beta of 2.27.
Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. Analysts forecast that Anavex Life Sciences Corp will post -0.63 EPS for the current fiscal year.
Anavex Life Sciences Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp (NASDAQ:AVXL).
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.